Wednesday 16 October 2019

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer
WOBURN, Mass. (October 16, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing facilities in the U.S., Australia, Germany and Singapore.
Read more

Thursday 10 October 2019

Sirtex Medical and China Grand Pharmaceutical announce a strategic transaction with OncoSec Medical Incorporated
PENNINGTON, N.J., Oct. 10, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (Nasdaq:ONCS), a late-stage intratumoral cancer immunotherapy company, today announced it entered into a strategic transaction with Grand Decade Developments Limited (Grand Decade), a direct, wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) (HKG:512), and its affiliate, Sirtex Medical US Holdings, Inc. (Sirtex).
Read more

Monday 24 June 2019

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres
WOBURN, Mass. (June 20, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cancer.* More than 1,000 healthcare providers and hospital systems across the globe offer this treatment.
Read more


Download PDF Download PDF

Languages:

Monday 01 April 2019

SIRT Approved for Routine Commissioning on the NHS
NHS England have announced that selective internal radiation therapy (SIRT) using yttrium-90 microspheres will be routinely commissioned for NHS patients with advanced colorectal cancer that has spread to the liver and is not responding to standard chemotherapies. The treatment will be available from April 2019.
Read more


Download PDF Download PDF

Languages:

Thursday 07 March 2019

Liver cancer: Selective Internal Radiation Therapy with SIR-Spheres® microspheres reimbursed in France
SIR-Spheres Y-90 resin microspheres will be reimbursed in France by the Health insurance for the treatment of selected patients with HCC. This decision results from the approval received from the Commission Nationale d’Évaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) on November 6th, 2018, which concluded that SIRT with SIR-Spheres had a therapeutic benefit in this disease. The reimbursement of SIR-Spheres will be effective from 20 March 2019 on.
Read more

Monday 03 July 2017

New Analysis Reveals First-Line Treatment Data on SIR-Spheres® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with right-sided primary tumours, compared to those receiving chemotherapy alone
Read more

Monday 05 June 2017

FOXFIRE Combined Analysis Results in First-Line Treatment of Metastatic Colorectal Cancer Presented at ASCO
Overall Survival (OS) findings reviewed in detail; Potential median OS benefit in mCRC patients with right-sided primary colon cancer
Read more

Monday 05 June 2017

SIR-Spheres® Y-90 Resin Microspheres Showed no Significant Difference in Overall Survival (OS) Compared to Sorafenib in Advanced HCC with Significantly Fewer Severe Adverse Events, New Asia-Pacific Study Finds
For the second time in less than two months, a major head-to-head study has shown that SIR-Spheres Y-90 resin microspheres, administered once directly to the liver offers important treatment benefits compared to twice-daily oral doses of sorafenib, the current standard of care for advanced hepatocellular carcinoma (primary liver cancer or HCC).
Read more


Download PDF Download PDF

Languages:

Wednesday 24 May 2017

Metastatic colorectal cancer patients treated first-line with SIR-Spheres® Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, REsect study shows
Surgeons’ blinded assessment of pre- and post-treatment CT scans of patients with previously unresectable colorectal cancer liver metastases treated in the SIRFLOX study presented at 12th Annual European-African HPB meeting.
Read more


Download PDF Download PDF

Languages:

Thursday 18 May 2017

American Society of Clinical Oncology (ASCO) publishes abstract of SIRveNIB, an Investigator-led Asia Pacific Primary Liver Cancer Study to be presented at ASCO Annual Meeting in Chicago, 4 June 2017
The SIRveNIB abstract published on-line in the Journal of Clinical Oncology states that treatment of locally advanced Hepatocellular Carcinoma (HCC) with a single treatment of SIR-Spheres® Y-90 resin microspheres results in Overall Survival not significantly different from twice-daily oral sorafenib, but with significantly better tumour response and fewer and less severe adverse events.
Read more

Monday 12 December 2016

NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases.
Read more

Monday 21 November 2016

ELPA Calls on Patients with Primary Liver Cancer (HCC) to Share their Experiences in First Global Survey
ELPA has recently joined a special partnership with similar organisations across North America, Asia and Europe to ask hundreds of men and women with primary liver cancer (HCC) to share their experiences by responding to the first-ever international survey of people living with HCC.
Read more

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage